NasdaqCM:CNXUBiotechs
How Investors Are Reacting To Conexeu Sciences (CNXU) Bolstering Leadership For CXU Device Commercialization
Earlier in June 2026, Conexeu Sciences Inc. expanded its leadership bench by adding three seasoned directors, appointing co-founder David Bogart as Chief Commercial Officer, and bringing aesthetics expert Melinda Farina onto its advisory board, while also updating key board committees.
These changes, paired with recent progress on scaling manufacturing and regulatory preparation for its CXU wound care device, highlight Conexeu’s push to turn its regenerative tissue platform into a commercial...